Clinical Trials

The main objective of this protocol is to allow us to use human peripheral blood samples from Caribbean patients, collected at Mayo Clinic under the approved IRB Number: 16-008485. Additional blood samples from patients consented under this IRB will also be used for this purpose. We will use these samples to isolate immune cells and perform single cell RNA sequencing. We hypothesize that the data obtained from this study will be instrumental in identifying RNA profiles specific to Latin American populations, providing vital information for the development of truly global therapeutic strategies that take into account diverse populations.

The purpose of this study is to collect, convert and bank blood cells from healthy volunteers into stem cells (iPSCs) at a current good manufacturing practice (cGMP) facility within the Discovery and Innovation building on the Mayo FLorida campus. After comprehensive validation, we will bank those cGMP-iPSCs as a resource available to Mayo Clinic investigators and also to outside investigators as appropriate. Those bio-specimens could be unique resources to develop new protocols for production of clinical grade iPSC-derived cells, cell-derived products such as extracellular vesicles, and tissues to support Investigational New Drug (IND) and related clinical trials.